FDA-Approved Mucinex 12HR Cold & Fever Multi-Symptom Brings 12-Hour OTC Relief for Cough, Fever, Pain

The FDA has approved Mucinex 12HR Cold & Fever Multi-Symptom (dextromethorphan hydrobromide/guaifenesin/naproxen sodium; Reckitt), a new over-the-counter (OTC) fixed-dose combination intended to provide up to 12 hours of relief from cough, chest congestion, fever, headache, and minor body pain associated with the common cold.¹ The product represents the first approved combination of these 3 active ingredients and is now available at retailers nationwide.¹˒²

Each extended-release tablet contains dextromethorphan HBr 30 mg, guaifenesin 600 mg, and naproxen sodium 110 mg, equivalent to 100 mg of naproxen.¹ Dextromethorphan acts as a cough suppressant, guaifenesin serves as an expectorant to loosen mucus and thin bronchial secretions, and naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that temporarily reduces fever and relieves minor aches and pains.¹

The product uses a bilayer extended-release formulation designed to support twice-daily dosing. Adults and children 12 years of age and older should take 2 extended-release tablets every 12 hours, with no more than 4 tablets taken within 24 hours. The tablets should be swallowed whole with a full glass of water and should not be crushed, chewed, or broken.¹

FDA Review Supports 12-Hour Dosing

Mucinex 12HR Cold & Fever Multi-Symptom was approved through a 505(b)(2) new drug application (NDA). Rather than requiring new efficacy trials demonstrating the effects of each individual ingredient, the application relied in part on the FDA's previous findings of safety and effectiveness for established products containing guaifenesin and dextromethorphan, as well as naproxen sodium.³

According to FDA review documents, the agency evaluated pharmacokinetic data designed to establish scientific bridges between the new combination and previously approved Mucinex DM and naproxen-containing products.³ The pivotal pharmacokinetic program supported the proposed 12-hour dosing interval, with FDA concluding that the submitted clinical pharmacology data adequately supported twice-daily administration.³

The approval is notable because there previously had not been a US-marketed product combining guaifenesin, dextromethorphan, and naproxen sodium in a single formulation.³ Mucinex DM, containing guaifenesin and dextromethorphan HBr, was first approved in 2004, whereas naproxen sodium has a long history of OTC use for pain and fever.³

Pharmacists Can Help Prevent Duplicate Therapy and NSAID-Related Risks

The multi-ingredient formulation also creates several important opportunities for pharmacist counseling. Because naproxen is included in the product, patients should be cautioned against unintentionally combining it with other prescription or OTC NSAIDs, including additional naproxen- or ibuprofen-containing products.¹

The Drug Facts labeling carries warnings regarding gastrointestinal bleeding and cardiovascular events associated with NSAID use. Risk for severe stomach bleeding may be greater among adults 60 years of age or older; individuals with a history of ulcers or bleeding disorders; and patients taking anticoagulants, corticosteroids, or other NSAIDs.¹ NSAIDs other than aspirin can also increase the risk of myocardial infarction, heart failure, and stroke, particularly when taken at higher-than-recommended doses or for longer than directed.¹

Patients taking aspirin for cardiovascular protection are instructed to consult a clinician before use because naproxen may interfere with aspirin's antiplatelet benefit. Individuals with hypertension, cardiovascular disease, kidney disease, liver cirrhosis, asthma, a history of stroke, or other conditions listed on the Drug Facts label should similarly speak with a health care professional before using the product.¹

Dextromethorphan adds additional medication-screening considerations. The product should not be used in patients currently taking a prescription monoamine oxidase inhibitor (MAOI) or within 2 weeks of discontinuing an MAOI.¹ Pharmacists can also help identify other medications containing dextromethorphan, guaifenesin, or pain relievers to reduce the potential for unintentional duplication.

Use is not recommended in children younger than 12 years. Patients who are pregnant or breastfeeding should consult a health professional before use, and naproxen should generally not be used at 20 weeks of pregnancy or later unless specifically directed by a clinician because of potential fetal and pregnancy-related complications.¹

Expanding the Role of Long-Acting OTC Symptom Management

The product enters the market as respiratory illnesses continue to create substantial seasonal demand for self-care therapies. During the 2024-2025 influenza season, CDC estimated tens of millions of influenza illnesses in the United States, along with millions of medical visits and hundreds of thousands of hospitalizations.⁴ The subsequent 2025-2026 season also showed substantial influenza activity early in the season, highlighting the continuing burden of respiratory disease.⁵

Although OTC therapies such as Mucinex 12HR Cold & Fever Multi-Symptom do not treat the underlying viral infection or replace influenza vaccination or indicated antiviral therapy, they can provide symptomatic relief for appropriate patients. For pharmacists, the availability of a longer-acting combination may offer another self-care option while increasing the importance of careful assessment of patients' symptoms, concomitant medications, comorbidities, and use of other combination cold and flu products.

REFERENCES

1. Mucinex 12HR Cold & Fever Multi-Symptom Drug Facts label. FDA. Updated June 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217338Orig1s000lbl.pdf?

2. Reckitt announces U.S. FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first OTC innovation in the cold & flu category in 14 years. Reckitt. August 5, 2026. https://www.reckitt.com/news/reckitt-announces-us-fda-approval-of-mucinex-12hr-cold-fever-multi-symptom-the-first-otc-innovation-in-the-cold-flu-category-in-14-years/

3. FDA. NDA 217338: Guaifenesin/Dextromethorphan Hydrobromide/Naproxen Sodium Multi-Disciplinary Review and Evaluation. US Food and Drug Administration. https://www.fda.gov/media/191873/download

4. Centers for Disease Control and Prevention. 2024-2025 US influenza season disease burden estimates. CDC. https://www.cdc.gov/flu-burden/php/data-vis-vac/2024-2025-prevented.html

5. Centers for Disease Control and Prevention. Weekly US Influenza Surveillance Report: 2025-2026 season. CDC. Accessed August 7th, 2026. https://www.cdc.gov/fluview/surveillance/2026-week-28.html